Safety and Feasibility of Kefir Administration in Critically Ill Adults

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

July 12, 2022

Primary Completion Date

February 4, 2023

Study Completion Date

December 3, 2023

Conditions
Critically Ill
Interventions
DIETARY_SUPPLEMENT

Kefir

Oral route (via feeding tube in intubated patients). Serving size 240mL to be given in an ascending dosing regimen if tolerated starting at 60 mL/day, 120 mL/day until single 240 mL/day; if evidence of intolerance, dose will be reduced to previously tolerated dose.

Trial Locations (1)

55905

Mayo Clinic Rochester, Rochester

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT05416814 - Safety and Feasibility of Kefir Administration in Critically Ill Adults | Biotech Hunter | Biotech Hunter